John Hancock U.S. Global Leaders Growth Fund Q4 2024 Commentary
For Q4 2024, the John Hancock U.S. Global Leaders Growth fund posted a small gain that trailed the return of its benchmark ...
John Hancock U.S. Growth Fund Q4 2024 Commentary
For Q4 2024, the John Hancock U.S. Growth Fund underperformed the benchmark Russell 1000 Growth Index. Click here to read the ...
Gorman-Rupp: A Pump Aristocrat Performing Soft On The Top-Line
Gorman-Rupp has grown its operations. Read why I require confirmation of growth and/or pullback in GRC share price before ...
Puma SE: Undervalued With Tailwinds Ahead
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements. Read why ...
TransMedics: The Financial Tipping Point That Will Drive Mass Adoption
TransMedics' NOP advances organ transplantation with improved outcomes & cost reductions. See why I rate TMDX stock a strong ...
Rapport Therapeutics: Too Early To Be Interesting
Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases. Check out my recommendation ...
Max Helfert
Max Helfert is a Master’s in Finance student at USC, pursuing a career in equity research. He specializes in healthcare innovation, leveraging a bottom-up approach to identify high-growth ...